IL2 and B-cell chronic lymphocytic leukemia: DEX was chosen as the cytotoxic agent for this trial based on its historical use in CLL and preclinical studies showing CLL cells under in vitro microenvironmental conditions involving treatment with a Toll‐like receptor agonist and IL‐2 could be killed by DEX in combination with ibrutinib and ruxolitinib but not with ibrutinib alone.